Scholarlink

Background <p>Lithium is a first-line maintenance treatment for bipolar disorder, but real-world persistence varies widely across health systems, and no incident-initiator cohort analysis of lithium has been reported from any Gulf Cooperation Council bipolar disorder population. We aimed to characterise lithium initiation, observed within-service treatment persistence, and post-discontinuation treatment pathways in a multinational tertiary psychiatric service in the United Arab Emirates.</p> Methods <p>A retrospective cohort study at a tertiary psychiatric service in the United Arab Emirates from 2018 to 2025. Among adults with a recorded ICD-10 F31 diagnosis, the incident initiator subset comprised adults whose first recorded lithium-bearing encounter occurred more than 90&#xa0;days after their first service contact. The primary outcome was observed treatment persistence within the health-system record. A patient was classified as having discontinued lithium when at least 90&#xa0;days elapsed with no lithium-bearing encounter; a 90-day grace period, reflecting routine dispensing intervals, was then added before the discontinuation date. Secondary outcomes included peri-initiation co-prescription and documented next-line treatment within 180&#xa0;days of discontinuation. Incident initiation was apparent within the study service only; prior or out-of-network lithium exposure could not be excluded.</p> Results <p>Among 135 incident initiators (median age 35&#xa0;years, 48.1% female, 31.1% Emirati), lithium was initiated a median of 556&#xa0;days after first service contact, most commonly during inpatient (43.0%) or outpatient (35.6%) encounters. Only 11.9% received lithium as a single recorded psychotropic; 82.2% had a concurrent antipsychotic, most commonly aripiprazole (40.0%). Estimated observed persistence was 25.0% (17.7 to 32.9) at 6&#xa0;months, 4.6% (1.7 to 9.8) at 12&#xa0;months, and 0.0% at 24&#xa0;months. The documented next-line treatment was most commonly an antipsychotic, with individually reported second-generation antipsychotics accounting for approximately three fifths of discontinuers. In exploratory adjusted analyses, no prespecified covariate was statistically associated with observed discontinuation.</p> Conclusions <p>Observed health-system-record persistence on lithium in this multinational cohort was very limited and substantially below international benchmarks, consistent with a mixture of true discontinuation, care transfer, out-of-network prescribing, and incomplete within-service medication capture. Strategies maintaining within-service visibility and cross-provider record linkage are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Electronic health record–observed lithium persistence after within-service initiation in bipolar disorder: an incident-initiator cohort study from a multinational tertiary psychiatric service in the United Arab Emirates

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月30日

查看全文
  • Syed Ali Bokhari,
  • Muhanad Elnoor,
  • Mohamed A. Alnor,
  • Syed Fahad Javaid

摘要

Background

Lithium is a first-line maintenance treatment for bipolar disorder, but real-world persistence varies widely across health systems, and no incident-initiator cohort analysis of lithium has been reported from any Gulf Cooperation Council bipolar disorder population. We aimed to characterise lithium initiation, observed within-service treatment persistence, and post-discontinuation treatment pathways in a multinational tertiary psychiatric service in the United Arab Emirates.

Methods

A retrospective cohort study at a tertiary psychiatric service in the United Arab Emirates from 2018 to 2025. Among adults with a recorded ICD-10 F31 diagnosis, the incident initiator subset comprised adults whose first recorded lithium-bearing encounter occurred more than 90 days after their first service contact. The primary outcome was observed treatment persistence within the health-system record. A patient was classified as having discontinued lithium when at least 90 days elapsed with no lithium-bearing encounter; a 90-day grace period, reflecting routine dispensing intervals, was then added before the discontinuation date. Secondary outcomes included peri-initiation co-prescription and documented next-line treatment within 180 days of discontinuation. Incident initiation was apparent within the study service only; prior or out-of-network lithium exposure could not be excluded.

Results

Among 135 incident initiators (median age 35 years, 48.1% female, 31.1% Emirati), lithium was initiated a median of 556 days after first service contact, most commonly during inpatient (43.0%) or outpatient (35.6%) encounters. Only 11.9% received lithium as a single recorded psychotropic; 82.2% had a concurrent antipsychotic, most commonly aripiprazole (40.0%). Estimated observed persistence was 25.0% (17.7 to 32.9) at 6 months, 4.6% (1.7 to 9.8) at 12 months, and 0.0% at 24 months. The documented next-line treatment was most commonly an antipsychotic, with individually reported second-generation antipsychotics accounting for approximately three fifths of discontinuers. In exploratory adjusted analyses, no prespecified covariate was statistically associated with observed discontinuation.

Conclusions

Observed health-system-record persistence on lithium in this multinational cohort was very limited and substantially below international benchmarks, consistent with a mixture of true discontinuation, care transfer, out-of-network prescribing, and incomplete within-service medication capture. Strategies maintaining within-service visibility and cross-provider record linkage are warranted.